Neuphoria Therapeutics
NEUP
3 hedge funds and large institutions have $1.54M invested in Neuphoria Therapeutics in 2022 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
0% less ownership
Funds ownership: 0% → 0% (-0%)
25% less funds holding
Funds holding: 4 → 3 (-1)
55% less capital invested
Capital invested by funds: $3.4M → $1.54M (-$1.86M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$162K |
NEUP Hedge Fund Activity: Q2 2022 in Review
3 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Neuphoria Therapeutics (NEUP) for Q2 2022, worth a combined $1.54M — down 55% from $3.4M a quarter earlier.
Fund positioning in NEUP was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was Woodline Partners, cutting an estimated $162K.
- 3 institutional investors held Neuphoria Therapeutics (NEUP) as of Q2 2022, down from 4 in Q1 2022.
- Funds reported $1.54M of Neuphoria Therapeutics stock for Q2 2022, down 55% quarter-over-quarter.
- 0 funds opened new Neuphoria Therapeutics positions in Q2 2022 and 0 closed out.
- The largest Neuphoria Therapeutics seller in Q2 2022 was Woodline Partners, an estimated $162K sold.
Based on aggregated 13F filings for Q2 2022.